Aivo Biosciences, Inc.
Biotechnology company developing small-molecule CNS therapeutics focused on M1 muscarinic receptor agonism. The team emphasizes medicinal chemistry to generate brain-penetrant, highly potent and subtype-selective small molecules and is advancing a lead M1 agonist candidate through preclinical development toward IND-enabling studies and first-in-human evaluation. Leadership reports experience across preclinical and clinical development, manufacturing, business development and fundraising.
Industries
N/A
Products
Lead M1 muscarinic receptor agonist candidate
A highly potent, subtype-selective, brain-penetrant small-molecule M1 receptor agonist candidate advanced through discovery and preclinical optimization toward IND-enabling studies.
Lead M1 muscarinic receptor agonist candidate
A highly potent, subtype-selective, brain-penetrant small-molecule M1 receptor agonist candidate advanced through discovery and preclinical optimization toward IND-enabling studies.
Services
Discovery and development of small-molecule CNS therapeutics
End-to-end small-molecule drug discovery and preclinical development focused on CNS indications, with pathways toward IND-enabling studies and clinical proof-of-concept.
Partnering and corporate presentations
Engagement with prospective collaborators and investors through conferences, partnered meetings, and corporate presentations to support partnerships and commercialization.
Discovery and development of small-molecule CNS therapeutics
End-to-end small-molecule drug discovery and preclinical development focused on CNS indications, with pathways toward IND-enabling studies and clinical proof-of-concept.
Partnering and corporate presentations
Engagement with prospective collaborators and investors through conferences, partnered meetings, and corporate presentations to support partnerships and commercialization.
Expertise Areas
- Small-molecule medicinal chemistry for CNS
- GPCR-targeted drug discovery (muscarinic M1)
- Preclinical and clinical development
- IND-enabling regulatory preparation
Key Technologies
- Small-molecule medicinal chemistry
- In silico modeling / computational chemistry
- Mass spectrometry
- In vitro pharmacology assays